BRIEF published on 02/02/2026 at 15:41, 4 months 19 days ago CHEPLAPHARM's Successful €950m Bond Issuance Refinancing Bond Issuance Financial Strategy Investor Demand CHEPLAPHARM
PRESS RELEASE published on 02/02/2026 at 15:36, 4 months 19 days ago Successful Refinancing: CHEPLAPHARM'S new 6.750% Bond multiple times oversubscribed CHEPLAPHARM successfully refinances with new 6.750% bond oversubscribed multiple times, enhancing financial flexibility and maturity profile Refinancing Oversubscribed Financial Flexibility CHEPLAPHARM 6.750% Bond
BRIEF published on 08/27/2025 at 13:34, 9 months 25 days ago CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
BRIEF published on 08/27/2025 at 13:34, 9 months 25 days ago CHEPLAPHARM annonce une croissance stable au premier semestre 2025 Croissance Des Revenus Industrie Pharmaceutique CHEPLAPHARM Programme De Transformation Expansion Des Employés
PRESS RELEASE published on 08/27/2025 at 13:29, 9 months 25 days ago CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRIEF published on 06/26/2025 at 10:36, 11 months 25 days ago L'obligation de 750 millions d'euros de CHEPLAPHARM connaît une forte demande et un prix attractif Obligations Confiance Des Investisseurs Médicaments Flexibilité Financière CHEPLAPHARM
BRIEF published on 06/26/2025 at 10:36, 11 months 25 days ago CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
PRESS RELEASE published on 06/26/2025 at 10:31, 11 months 25 days ago High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed CHEPLAPHARM successfully places €750m senior secured notes at 7.125% interest rate, enhancing financial flexibility and extending maturity profile, oversubscribed transaction Senior Secured Notes Oversubscribed Financial Flexibility CHEPLAPHARM 7.125%
BRIEF published on 06/02/2025 at 10:34, 1 year ago Sandra Schröder Joins CHEPLAPHARM as VP Scientific Pharmaceutical Regulatory Affairs Quality Management CHEPLAPHARM Sandra Schröder
BRIEF published on 06/02/2025 at 10:34, 1 year ago Sandra Schröder rejoint CHEPLAPHARM en tant que vice-présidente scientifique Pharmaceutique Affaires Réglementaires Gestion De La Qualité CHEPLAPHARM Sandra Schröder
Published on 06/20/2026 at 01:00, 1 day 18 hours ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 19 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 15 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 18 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 18 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 22 hours 13 minutes ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 13 hours ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 23 hours ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 1 day 23 hours ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 2 days ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 2 days ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 2 days ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 2 days ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 2 days ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
